The brain is wrapped in a selective barrier, a tightly regulated wall built from specialized cells that controls what enters and exits brain tissue. After a traumatic brain injury, that wall can crack. Blood vessels leak, fluid accumulates, and the mismatch between the body's attempt to grow new vessels and its ability to maintain those vessels can actually make things worse before they get better.
A study published in Scientific Reports set out to understand whether a GLP-1 receptor agonist peptide, known generically as semaglutide, could improve that repair process in mice. The researchers used a controlled impact model to simulate traumatic brain injury and then tracked a series of molecular signals to map out exactly how the peptide appeared to stabilize blood vessels and encourage the growth of new ones in a more coordinated way.
What they found was a multi-step signaling cascade, a chain of molecular events triggered by the peptide that linked pericytes, a type of support cell wrapped around blood vessels, to the endothelial cells that line those vessels. Understanding that chain offers a clearer picture of what goes wrong after brain injury and what might, in principle, help correct it.
The blood-brain barrier and why repair is complicated
The blood-brain barrier is not a single structure but a collaborative system. Endothelial cells form the inner lining of brain blood vessels, held together by proteins called tight junction proteins that act like molecular zippers, preventing unwanted molecules from slipping through. Wrapped around the outside of those endothelial cells are pericytes, support cells that help regulate vessel stability, permeability, and survival.
After a traumatic brain injury, both cell types are disrupted. Tight junction proteins break down, pericytes detach or die, and the barrier becomes leaky. The brain then tries to grow new blood vessels, a process called angiogenesis, but if those new vessels form before the barrier proteins are in place, they can make edema, swelling from fluid accumulation, significantly worse. The researchers framed this mismatch as a central problem in traumatic brain injury recovery.
The mouse model used in the study
To study this process, the research team used a controlled cortical impact model in mice. This is a well-established laboratory method that delivers a precise mechanical injury to the brain, reliably producing the kind of vascular disruption and tissue damage seen in human traumatic brain injury. Animals in the study were then treated with semaglutide, and researchers examined both the injury site and the tissue around it at the molecular level.
The team measured a range of markers: tight junction protein levels, pericyte survival, endothelial cell behavior, brain edema, and markers of neurological function. They also looked at the activity of specific growth factor receptors and downstream signaling proteins to build a mechanistic picture of how the peptide was influencing the tissue.
The PDGF-BB signaling cascade
The study identified platelet-derived growth factor BB, commonly abbreviated PDGF-BB, as the first major step in the signaling chain triggered by semaglutide. In the tissue surrounding the injury, the peptide appeared to upregulate PDGF-BB expression, meaning the tissue produced more of this growth factor than it would have without the treatment.
PDGF-BB is known to act on pericytes through a receptor called PDGFR-beta. When PDGF-BB binds to that receptor, the pericytes respond by secreting two other signaling molecules: angiopoietin-1, often called Ang-1, and vascular endothelial growth factor, or VEGF. Both of these molecules play important roles in blood vessel formation and stabilization.
The researchers described this as a cascade, where semaglutide effectively activated PDGF-BB, which then activated pericytes through PDGFR-beta, which then released Ang-1 and VEGF to act on endothelial cells. Each step in that chain contributed to both new vessel growth and to the structural integrity of the barrier.
Ang-1, Tie2, and tight junction proteins
Ang-1 acts on endothelial cells through a receptor called Tie2. The Ang-1 and Tie2 interaction is associated with vessel stabilization, reduced permeability, and improved pericyte-to-endothelial cell communication. In the study, activation of this pathway was linked to better survival of both cell types at the injury site.
Alongside Ang-1 signaling, the researchers observed upregulation of tight junction proteins in treated animals. These are the structural proteins that keep the molecular zippers of the blood-brain barrier closed. Higher levels of tight junction proteins suggest a more intact barrier, which the team associated with reduced brain edema in the treated mice.
The study also identified involvement of the PI3K and AKT signaling pathway, a well-known intracellular route that promotes cell survival and growth. The researchers suggested this pathway contributes to the protective interactions between endothelial cells and pericytes that semaglutide appeared to facilitate.
Angiogenesis and neurological function outcomes
Beyond barrier repair, the study found that the peptide treatment was associated with increased angiogenesis in the area surrounding the injury. New blood vessel formation is important for delivering oxygen and nutrients to tissue that has been damaged, and the literature suggests that coordinated angiogenesis, where new vessels form with intact barrier properties from the start, is far more beneficial than the leaky, poorly organized vessel growth that often follows injury.
The mice treated with semaglutide showed markers consistent with more organized vascular regrowth, and the researchers reported improvements in neurological function recovery measures compared to untreated animals. The study authors noted that the pericyte-endothelial cell axis appeared central to this improvement, as both cell types need to survive and communicate effectively for coordinated vessel formation to occur.
Limitations and context for this research
This research was conducted entirely in mice using a controlled cortical impact model. While this model is widely used and produces reproducible injury, mouse brain physiology differs from human brain physiology in meaningful ways. The molecular pathways identified here will require validation in other model systems and, eventually, in human studies before any clinical conclusions can be drawn.
The study also focused on a specific window of time after injury. The literature on traumatic brain injury consistently shows that timing matters in vascular repair, and it is not yet clear from this work how the timing of peptide administration relative to injury affects the outcomes observed.
Finally, semaglutide is a GLP-1 receptor agonist with multiple known effects on metabolism, inflammation, and neuroprotection. The researchers acknowledged that the PDGF-BB pathway they described is unlikely to be the only mechanism at work. Other anti-inflammatory or metabolic effects of GLP-1 signaling may also contribute to the outcomes measured. The study highlighted the vascular signaling pathway as a previously undefined mechanism, adding a new layer to an already complex pharmacological profile.
